What is the market price range of acotinib/acalabrutinib?

Acalabrutinib (Acalabrutinib) is a second-generation BTK inhibitor that is used to treat a variety of hematological tumors derived from B cells. It has been widely used in chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma. By blocking theBCR signaling pathway, it effectively inhibits the proliferation and anti-apoptotic ability of tumor cells, which can not only delay disease progression, but also significantly improve patient survival time and quality of life. With the development of precision medicine, acotinib is gradually regarded as a key option for patients who have been resistant to chemotherapy or cannot tolerate traditional treatments.

In China, acotinib has been marketed under the trade name "Kangkeqi" and has been included in the medical insurance catalog. Its dosage form is oral capsule, the common specification is 100mg, 8 capsules per box, 7 plates in total, 56 capsules in total, the overall price is about 20,000 yuan. Although the price of a single box is not low, due to the inclusion of medical insurance, the actual cost paid by patients has been greatly reduced, which has significantly improved the accessibility of the drug. Compared with previous generation BTK inhibitors such as ibrutinib, acotinib's reimbursement policy within the scope of medical insurance further reduces the financial burden on families, making it a more acceptable long-term medication option for clinicians and patients.

In overseas markets, the original drug price of acotinib is higher, especially in European and American countries, often exceeding tens of thousands of yuan per box. With the emergence of generic drugs, the price gap has rapidly widened. At present, some Asian countries and regions, such as Laos and Bangladesh, have already launched generic versions of acotinib. For example, the generic version of acotinib produced by a Lao pharmaceutical company is 100mg*60 capsules, and the price per box is about more than 2,000 yuan. Although generic drugs have more advantages in terms of price, patients need to pay special attention to the formality of the channels and drug quality when choosing to avoid treatment risks caused by unknown drug sources.

Reference materials:https://www.calquence.com/